Unilever will not raise rejected 50 bln pound bid for GSK consumer arm


GSK has rejected three bids from Unilever for its consumer arm, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller, saying the bids "fundamentally undervalued" the business and its prospects. It has said it would stick to its plan to separately list the business in mid-2022 and issued improved financial assumptions for the unit.

Unilever PLC on Wednesday effectively abandoned its plans to buy GlaxoSmithKline's consumer healthcare business, saying that it would not raise its 50 billion pound ($68 billion) offer that GSK previously rejected.

U.S.-listed shares of Unilever rose 10.1% on the news, while GSK's fell 2.8%. The two stocks also trade on the FTSE, where the day's trading had closed.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

PETRONAS’ PIC investments now at RM7.5bil
KIP-REIT buys retail asset in Perak
Stable outlook for banking sector
Sunway-REIT posts positive showing
Teo Seng posts stronger third-quarter results
WCE Holdings shareholder in warrant exercise
MR DIY announces improved dividends for 3Q
PM Anwar to participate in APEC CEO Summit, meet Google
CapitaLand Malaysia Trust appoints Yong Su-Lin as CEO designate
Keyfield's net profit higher at RM81.1mil in 3Q

Others Also Read